5-Fluoro-2'-deoxycytidine is a fluoropyrimidine nucleoside analogue and a DNMT inhibitor. 5-Fluoro-2'-deoxycytidine is a tumour-selective prodrug of 5-fluoro-2′-dUMP[1][2].
5-Fluoro-2'-deoxycytidine/5-氟脱氧胞苷 细胞实验
Cell Line
Concentration
Treated Time
Description
References
KYSE150
1 μM
72 h
FCdR inhibited KYSE150 cell proliferation with a survival rate of about 30%.
Springerplus. 2012 Dec;1(1):65
U2OS
1 μM
72 h
FCdR inhibited U2OS cell proliferation with a survival rate of about 80%.
Springerplus. 2012 Dec;1(1):65
HEPG2
1 μM
72 h
FCdR inhibited HEPG2 cell proliferation with a survival rate of about 40%.
Springerplus. 2012 Dec;1(1):65
dCMPD-/TK- double mutant S-49 cells
1 μM
Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking both dCMP deaminase and thymidine kinase, showing significantly reduced toxicity.
Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
dCMPD- mutant S-49 cells
3 nM
Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking dCMP deaminase, showing reduced toxicity.
Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
dCK- mutant S-49 cells
20 nM
Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking deoxycytidine kinase, showing reduced toxicity.
Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
TK- mutant S-49 cells
10 nM
Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking thymidine kinase, showing reduced toxicity.
Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
S49 mouse lymphoma cells
2 nM
Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cell growth, showing it primarily acts by inhibiting thymidylate synthetase.
Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
Caki-1 PBRM1-/-
10uM
72 h
To screen for synthetic lethal drugs in PBRM1-deficient renal cancer cells
Front Oncol. 2022 Jun 3;12:870229
Caki-1 PBRM1+/+
10uM
72 h
To screen for synthetic lethal drugs in PBRM1-deficient renal cancer cells
Front Oncol. 2022 Jun 3;12:870229
Human ependymoma PDX
8.3 nM
72 h
To evaluate the inhibitory effect of FdCyd on human ependymoma PDX cell proliferation, showing an EC50 of 8.3 nM.
J Neurooncol. 2016 Jan;126(2):225-34
Human G3 medulloblastoma PDX (TB-12-5950)
1 nM
72 h
To evaluate the inhibitory effect of FdCyd on human G3 medulloblastoma PDX cell proliferation, showing an EC50 of 1 nM.
J Neurooncol. 2016 Jan;126(2):225-34
Mouse choroid plexus carcinoma (CPC)
5.6 nM
72 h
To evaluate the inhibitory effect of FdCyd on choroid plexus carcinoma cell proliferation, showing an EC50 of 5.6 nM.
J Neurooncol. 2016 Jan;126(2):225-34
Mouse ependymoma (EP)
4 nM
72 h
To evaluate the inhibitory effect of FdCyd on ependymoma cell proliferation, showing an EC50 of 4 nM.
J Neurooncol. 2016 Jan;126(2):225-34
Mouse G3 medulloblastoma (Myc1)
1.7 nM
72 h
To evaluate the inhibitory effect of FdCyd on G3 medulloblastoma cell proliferation, showing an EC50 of 1.7 nM.
J Neurooncol. 2016 Jan;126(2):225-34
5-Fluoro-2'-deoxycytidine/5-氟脱氧胞苷 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
CD1 nude mice
G3 medulloblastoma, ependymoma, and choroid plexus carcinoma models
Intravenous injection
6 mg/kg
5 days treatment followed by 2 days off for 2 weeks for a 4-week cycle
To evaluate the in vivo efficacy of FdCyd and THU combination therapy in G3 medulloblastoma, ependymoma, and choroid plexus carcinoma models, showing no significant tumor growth inhibition.
J Neurooncol. 2016 Jan;126(2):225-34
BALB/c nude mice
786-O PBRM1+/+ and PBRM1-/-#1 xenograft model
Oral
25mg/kg
Daily for 21 days
To evaluate the synthetic lethal effect of Fdcyd in PBRM1-deficient renal cancer
搜索
